Jiun-Ruey Hu

Mar 28, 2024 | jamanetwork.com | Jiun-Ruey Hu |Yasser Jamil |Michelle D. Kelsey |W. Schuyler Jones

Key PointsQuestion  What is the optimal duration of dual antiplatelet therapy (DAPT) in terms of net adverse clinical events, major cardiovascular events, and bleeding for older adults after percutaneous coronary intervention (PCI)? Findings  In this systematic review and network meta-analysis of 14 randomized clinical trials, no differences in net adverse clinical events and major adverse cardiovascular events were seen for 1, 3, 6, and 12 months of DAPT.